New Defibrillators Treat Heart Failure and Sudden Cardiac Death

Both devices offer features based on significant engineering advances, including extended battery longevity, self-correcting software, and improved programming technology. Both devices also offer SafetyCore, a feature that in the unlikely event of a system error provides lifesaving shock therapy and basic pacing functionality.

Among the key features of the Cognis are SmartDelay programmable device settings, which enables physicians to tailor individualized pacing therapy for their patients; Bi-V Trigger, which helps physicians manage heart failure patients with frequent atrial arrhythmias; and Electronic Repositioning, a feature that provides physicians with six configurations for stimulating the left side of the heart even after implant, which may help avoid an additional surgical procedure.

Key features of the Teligen ICD include a reverse mode switch, designed to eliminate unnecessary ventricular pacing; and the Quick Convert feature, which provides the ability for patients to receive pacing therapy for ventricular tachycardias. Both products are manufactured by Boston Scientific (MA, USA), and are pending approval by the U.S. Food and Drug Administration (FDA).

"We have re-engineered the way we design, build, test, and report on our technology,” said Jim Tobin, President and CEO of Boston Scientific. "The Cognis CRT-D and the Teligen ICD are testaments to the revitalization of our CRM business and are just two of the many new products we plan to launch in 2008.”


Related Links:
Boston Scientific